Introduction: DME in vitrectomized eyes

Diabetic Macular Edema (DME) is the most frequent cause of vision loss related to diabetes.

The etiology of DME is multifactorial, and different treatment modalities are targeting to different triggering factors.

The spectrum of treatment options include corticosteroids, anti-vascular endothelial growth factor agents, laser treatment, combined therapy, pars plana vitrectomy, even if no epiretinal membrane is present.

The beneficial effect of vitrectomy on diabetic macular edema is attributed to improved oxygenation of the retina. However many patients may require drug therapy following the surgical procedure. The widespread distribution and increased circulation of intra-vitreally administered drugs in vitrectomized eyes might be rensposible for rapid clearance and reduced effectiveness of drug therapy. In vitrectomized eyes, sustained-release drugs could be particular useful.